Could a Low-Dose drug ease POTS fatigue? new trial aims to find out
NCT ID NCT05363514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether low dose naltrexone (LDN) can reduce fatigue in people with Postural Orthostatic Tachycardia Syndrome (POTS). Eighty participants will receive either LDN or a placebo for 4 months. The goal is to see if LDN improves fatigue and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- low dose naltrexone (LDN)
- What this could lead to
- If it works, this could point toward a new treatment for fatigue in POTS patients, improving their daily quality of life.
- What could go wrong
- This is a small pilot study, so results may not be conclusive. The drug may not reduce fatigue more than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a High-Fat diet reset energy in long COVID?
- Scientists map the many faces of POTS to unlock better care
- Can tailored exercise help tame racing heart and fatigue after COVID?
- Can immune therapy IVIG calm long COVID's autonomic storm?
- Can tight clothing tame POTS symptoms?
- Can extra salt calm racing hearts? new POTS study aims to find out